In FDA Appeal, Genentech Proposes Biomarker Strategy to Keep Avastin Available for Best Responders

Genentech is proposing to conduct a randomized, controlled confirmatory trial that "would include a biomarker component to identify patients who may be more likely to derive a more substantial benefit from Avastin." Such a strategy would align with FDA's personalized medicine focus, the company points out.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.